Program
Cisplatin
Also written as “cisplatin”, “docetaxel and cisplatin” and “Pemetrexed/Cisplatin”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms · Stomach Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms, led by 21 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 490 open or running | phase 3since Sep 12, 2005 | Jan 10, 2003 | none ahead |
| Sanofi | 150 open or running | phase 4since Oct 13, 2008 | Jun 6, 2001 | none ahead |
| Hoffmann-La Roche | 130 open or running | phase 3since Aug 18, 2009 | Apr 17, 2008 | none ahead |
| Bristol-Myers Squibb | 80 open or running | phase 3since Jun 14, 2006 | Jun 14, 2006 | none ahead |
| Pfizer | 60 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| Otsuka | 30 open or running | phase 3since Jun 30, 2005 | Nov 10, 2003 | none ahead |
| Sino Biopharmaceutical | 20 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| academy-military-medical-science-china | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| allarity-therapeutics | 10 open or running | phase 2since May 1, 2013 | May 1, 2013 | none ahead |
| Bayer | 10 open or running | phase 2since Jul 27, 2006 | Jul 27, 2006 | none ahead |
| cbsbioscience | 10 open or running | phase 2since Nov 10, 2016 | Nov 10, 2016 | none ahead |
| coherus-oncology-inc | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| CSPC Pharmaceutical Group | 10 open or running | phase 2since Dec 11, 2017 | Dec 11, 2017 | none ahead |
| Eisai | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| eleison-pharmaceuticals-llc | 10 open or running | phase 2since Jul 20, 2012 | Jul 20, 2012 | none ahead |
| healthcare-global-enterprise-ltd | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| hope-cancer-institute-inc | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| jiangsu-healthy-life-innovation-medical-technology-co-ltd | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| NovoCure | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Jan 9, 2009 | Jan 9, 2009 | none ahead |
| zivena | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: AstraZeneca, Merck, Ono Pharmaceutical, parexel, Daiichi Sankyo, Halozyme Therapeutics, biolinerx-ltd, quintiles-inc, pharmabio-development-inc, Takeda and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jun 21, 2007.
- Dec 16, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT02998528 · 505 enrolled · United States, Argentina, Brazil and more
- Jan 27, 2017Phase 3 study in Urothelial CancerBristol-Myers Squibb · NCT03036098 · 1,314 enrolled · United States, Argentina, Australia and more
- May 4, 2017Phase 3 study in Various Advanced CancerBristol-Myers Squibb · NCT03143153 · 970 enrolled · United States, Argentina, Australia and more
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Nov 17, 2017Phase 3 study in Squamous Cell Carcinoma of Head and NeckBristol-Myers Squibb · NCT03349710 · 74 enrolled · United States, France, Italy and more
- Dec 11, 2017CSPC Pharmaceutical Group's first study: phase 2 study in Poorly Differentiated Thyroid CarcinomaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03387943 · 30 enrolled · China
- Jul 17, 2018Sino Biopharmaceutical's first study: phase 3 study in Nasopharyngeal CarcinomaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03601975 · 336 enrolled · China
- Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellHoffmann-La Roche · NCT03869190 · 272 enrolled · United States, France, Greece and more
- Nov 4, 2020Phase 2 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04622228 · 56 enrolled · China
- Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
- Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaSino Biopharmaceutical · NCT05834543 · 34 enrolled · China
- Jun 10, 2024coherus-oncology-inc's first study: phase 4 study in Nasopharyngeal NeoplasmsNew to coherus-oncology-inccoherus-oncology-inc · NCT06457503 · 100 planned · United States, Canada
- Sep 20, 2024jiangsu-healthy-life-innovation-medical-technology-co-ltd's first study: no phase study in Biliary Tract NeoplasmsNew to jiangsu-healthy-life-innovation-medical-technology-co-ltdjiangsu-healthy-life-innovation-medical-technology-co-ltd · NCT06611345 · 60 planned · China
- Oct 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT06624059 · 11 enrolled · Australia, Brazil, Chile and more
Ahead
- Dec 2027Primary completion: phase 4 study in Nasopharyngeal Neoplasmscoherus-oncology-inc · NCT06457503
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 110 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06624059Carcinoma, Non-Small-Cell Lung · Australia, Brazil, Chile and more | 3 | Completed | Hoffmann-La Roche | Jul 31, 2026 | 11 |
| NCT06611345Biliary Tract Neoplasms · China | – | Recruiting | jiangsu-healthy-life-innovation-medical-technology-co-ltd | Oct 30, 2026 | 60 |
| NCT06457503Nasopharyngeal Neoplasms · United States, Canada | 4 | Recruiting | coherus-oncology-inc | Dec 2027 | 100 |
| NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | Sino Biopharmaceutical | Oct 23, 2024 | 34 |
| NCT05136677Mesothelioma, Malignant · China | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2025 | 102 |
| NCT04622228Small Cell Lung Carcinoma · China | 2 | Completed | Hoffmann-La Roche | Jun 21, 2022 | 56 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Hoffmann-La Roche | Oct 8, 2025 | 272 |
| NCT03601975Nasopharyngeal Carcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 30, 2020 | 336 |
| NCT03387943Poorly Differentiated Thyroid Carcinoma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2018 | 30 |
| NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more | 3 | Completed | Bristol-Myers Squibb | Oct 14, 2019 | 74 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 18, 2021 | 970 |
| NCT03036098Urothelial Cancer · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Aug 30, 2024 | 1,314 |
| NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Sep 8, 2021 | 505 |
| NCT02967887Hepatocellular Carcinoma Non-Resectable · Korea, Republic of | 2 | UNKNOWN | cbsbioscience | Oct 2018 | 96 |
| NCT02985255Tongue Neoplasms · India | 2 | UNKNOWN | healthcare-global-enterprise-ltd | Jun 2017 | 30 |
| NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2022 | 1,213 |
| NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more | 2 | Completed | Hoffmann-La Roche | Nov 2009 | 45 |
| NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Oct 25, 2024 | 2,747 |
| NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more | 2 | Completed | NovoCure | Apr 2018 | 82 |
| NCT02061631Squamous Cell Carcinoma of Head and Neck · Pakistan | 2 | Completed | Sanofi | Jul 2015 | 35 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Hoffmann-La Roche | Jan 2010 | 13 |
| NCT01911598Head and Neck Neoplasms · United States, Belgium | 1 | Completed | Hoffmann-La Roche | Jun 22, 2017 | 24 |
| NCT01861496Prostatic Neoplasms · Denmark | 2 | Completed | allarity-therapeutics | Oct 2021 | 50 |
| NCT01650090Osteosarcoma · United States | 2 | Completed | eleison-pharmaceuticals-llc | Nov 2018 | 28 |
| NCT01606748Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Eli Lilly | Jun 2013 | 35 |
| NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 296 |
| NCT01285557Stomach Neoplasms · United States, Argentina, Belgium and more | 3 | Terminated | Otsuka | Aug 15, 2014 | 361 |
| NCT01266512Lung Neoplasms · Hong Kong | 2 | Completed | Sanofi | Mar 2014 | 34 |
| NCT01165021Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | Eli Lilly | Jul 2013 | 19 |
| NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more | 2 | Terminated | Eisai | May 8, 2015 | 92 |
| NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico | 2 | Completed | Eli Lilly | Sep 2012 | 72 |
| NCT01099358Head and Neck Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Oct 2015 | 47 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Eli Lilly | Aug 2013 | 69 |
| NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico | 2 | Completed | Eli Lilly | Aug 2013 | 187 |
| NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more | 2 | Completed | Eli Lilly | Feb 2012 | 66 |
| NCT01038661Lung Neoplasms · China | 3 | Completed | Sanofi | Aug 2012 | 375 |
| NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more | 3 | Completed | Eli Lilly | Apr 2013 | 236 |
| NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more | 2 | Completed | Eli Lilly | Nov 2012 | 109 |
| NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more | 2 | Completed | Eli Lilly | Jan 2013 | 90 |
| NCT00995293Head and Neck Neoplasms · China | 3 | Completed | Sanofi | Jan 26, 2018 | 240 |
| NCT00961415Non-Squamous Non-Small Cell Lung Cancer · France, Germany, Greece and more | 3 | Completed | Hoffmann-La Roche | May 2011 | 376 |
| NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom | 2 | Completed | Eli Lilly | Jul 2010 | 70 |
| NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more | 2 | Completed | Eli Lilly | May 2011 | 113 |
| NCT00821327Urothelial Cancer · United States | 2 | Completed | Sarah Cannon Research Institute | Aug 2012 | 36 |
| NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more | 3 | Completed | Eli Lilly | Jun 2010 | 939 |
| NCT00776698Non-Squamous Non-Small Cell Lung Cancer · Netherlands, United Kingdom | 1 | Completed | Hoffmann-La Roche | Feb 2010 | 1 |
| NCT00773188Non-Squamous Non-Small Cell Lung Cancer · Canada | 1 | Completed | Hoffmann-La Roche | Oct 2010 | 6 |
| NCT00772863Ovarian Neoplasms · Turkey | 2 | Completed | Sanofi | Jun 2008 | 37 |
| NCT00772681Head and Neck Neoplasms · Turkey | 4 | Completed | Sanofi | Mar 2008 | 57 |
| NCT00717951Advanced Breast Cancer | 2 | UNKNOWN | academy-military-medical-science-china | Dec 2009 | 120 |
| NCT00661778Carcinoma, Non-Small-Cell Lung · Spain | 2 | Completed | Hoffmann-La Roche | Jul 2011 | 50 |
| NCT00555672Stomach Neoplasms · Spain | 1 | Completed | Pfizer | Dec 2009 | 34 |
| NCT00555620Stomach Neoplasms · Korea, Republic of | 1 | Completed | Pfizer | Aug 2010 | 76 |
| NCT00553696Stomach Neoplasms · Japan | 1 | Completed | Pfizer | Jul 2009 | 27 |
| NCT00528619Neoplasms · United States, Canada | 1 | Completed | Pfizer | Apr 2010 | 96 |
| NCT00496275Carcinoma, Non-Small-Cell Lung | 1 | Completed | Sanofi | 17 | |
| NCT00491127Lymphoma, Non-Hodgkin · Spain | 2 | Completed | Eli Lilly | 10 | |
| NCT00490880Urinary Bladder Neoplasms · Poland | 2 | Completed | Eli Lilly | 2 | |
| NCT00490659Carcinoma, Non-Small-Cell Lung · Poland | 2 | Completed | Eli Lilly | 13 |
How it is read
Names in the registry
- “Cisplatin”, 86 entries
- “cisplatin”, 51 entries
- “docetaxel and cisplatin”, 3 entries
- “Pemetrexed/Cisplatin”, 2 entries
- “CISPLATIN”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 58 studies
- Head and Neck Neoplasms, 17 studies
- Stomach Neoplasms, 12 studies
- Small Cell Lung Carcinoma, 7 studies
- Breast Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.